Montelukast Sodium
2-[1-[[1-[3-[2-[(7-Chloro-2-Quinolyl)]Vinyl]Phenyl]-3-[2-(1-Hydroxy-1-Methyl-Ethyl)Phenyl]-Propyl]Sulfanylmethyl]Cyclopropyl]Acetic Acid Sodium Salt, 1-[1-[[[(1R)-1-[3-[(1E)-2-(7-Chloro-2-Quinolinyl)Ethenyl]Phenyl]-3-[2-(1-Hydroxy-1-Methylethyl)Phenyl]Propyl]Thio]Methyl]Cyclopropaneacetic, Montelukast Sodium
Description
Montelukast Sodium is the orally bioavailable monosodium salt of montelukast, a selective cysteinyl leukotriene receptor antagonist with anti-inflammatory and bronchodilating activities. Montelukast selectively and competitively blocks the cysteinyl leukotriene 1 (CysLT1) receptor, preventing binding of the inflammatory mediator leukotriene D4 (LTD4). Inhibition of LTD4 activity results in inhibition of leukotriene-mediated inflammatory events including: migration of eosinophils and neutrophils; adhesion of leukocytes to vascular endothelium, monocyte and neutrophil aggregation; increased airway edema; increased capillary permeability; and bronchoconstriction. The CysLT1 receptor is found in a number of tissues including spleen, lung, placenta, small intestine, and nasal mucosa, and in a variety of cell types including monocyte/macrophages, mast cells, eosinophils, CD34-positive hemopoietic progenitor cells, neutrophils and endothelial cells.
Additional information
Generic | |
---|---|
CAS No | 151767-02-1 |